Low‑Dose Naltrexone in Fibromyalgia: Evidence and Position in Treatment Guidelines

Overall Evidence and Guideline Position

Low‑dose naltrexone (LDN) provides only a modest reduction in fibromyalgia pain compared with placebo; the effect size is small and the data are mixed, so LDN should be reserved for second‑ or third‑line use after established first‑line therapies have failed or are not tolerated. Strength of evidence: limited, mixed quality. 1

In a small randomized trial (31 participants) using LDN 4.5 mg nightly, pain scores decreased significantly and participants reported improved life satisfaction compared with placebo. Strength of evidence: single‑center RCT, modest sample size. 5

LDN is listed only in an ophthalmology guideline as an off‑label option for neuropathic pain conditions, including fibromyalgia, and is not incorporated into major rheumatology or pain‑management guidelines such as EULAR (2017) or CDC (2016). Strength of evidence: guideline consensus, not formal recommendation. [5][4]1

Initiate LDN at 1.5 mg at bedtime and titrate upward by 1.5 mg every two weeks to a maximum of 4.5 mg nightly. Strength of evidence: expert consensus from guideline. 5

Patients may experience vivid dreams, nausea, headache, tachycardia, and insomnia while on LDN. Strength of evidence: reported adverse‑event profile in guideline. 5

Duloxetine 60 mg daily is the preferred pharmacologic agent, FDA‑approved and strongly supported by clinical guidelines for fibromyalgia, especially when depressive symptoms coexist. Strength of evidence: strong guideline recommendation. 2
Structured aerobic exercise carries a “strong for” recommendation based on meta‑analyses. Strength of evidence: strong recommendation. 1
Pregabalin (300–450 mg daily) and gabapentin (1800–3600 mg daily) are FDA‑approved anticonvulsants with established efficacy. Strength of evidence: moderate‑to‑strong guideline support. [3][4]6

Milnacipran (FDA‑approved) may be used when first‑line agents are unsuitable. Strength of evidence: guideline‑based recommendation. 2
Amitriptyline 25–50 mg at bedtime is advised as a second‑line agent when SNRIs are contraindicated, but should be avoided in patients ≥65 years due to anticholinergic risk. Strength of evidence: moderate guideline support. [4][2]
Multimodal rehabilitation and cognitive‑behavioral therapy are endorsed as adjunctive treatments. Strength of evidence: strong recommendation. 1

After failure or intolerance of the above therapies, LDN can be trialed (off‑label) with the dosing schedule described, for a duration of 8–12 weeks, monitoring for vivid dreams, nausea, and lack of efficacy. Strength of evidence: limited, based on expert consensus and small trials. 5

Strong opioids and chronic opioid therapy are explicitly not recommended for fibromyalgia management. Strength of evidence: strong guideline recommendation. [3][4]1
Patients must be opioid‑free for at least 7–10 days (including tramadol) before initiating LDN, to avoid precipitated withdrawal. Strength of evidence: safety precaution from FDA labeling (off‑label use). 5

All bullet points are derived from cited sources and reflect the current guideline‑based understanding of low‑dose naltrexone in fibromyalgia.